Skip to main content
TipRanks
Go Ultimate75% OFF

Humana (HUM) AI Stock Analysis

2,757 Followers
HUM

Humana

(NYSE:HUM)

Select Model
Rating:64Neutral
Price Target:$441.00â–¼(-0.53% Downside)
Action:reiterated
Date:11/06/26

HUM scores in the mid-range because improved guidance and upbeat earnings-call momentum (raised 2026 EPS outlook and strong Stars performance) are offset by weakened underlying profitability/returns in recent financials and a high valuation multiple. Technicals are constructive longer-term but currently neutral, providing limited incremental support.

Positive Factors
Strong Revenue GrowthHumana has expanded revenue substantially across its insurance and healthcare-services platform, demonstrating meaningful scale and continued demand. Although growth has slowed from earlier periods, the larger revenue base can support operating investments, care capabilities, and broader member reach over the next several quarters.
Negative Factors
Compressed ProfitabilityProfitability has deteriorated materially despite continued revenue growth, indicating that scale has not yet translated into comparable earnings quality. Lower net, EBIT, and EBITDA margins reduce financial resilience and leave less capacity to absorb adverse medical costs or fund strategic initiatives internally.

Humana Key Performance Indicators (KPIs)

Revenue by SegmentBreaks down sales figures for each business unit, indicating which areas are contributing most to growth and where there might be potential for expansion or risk.

-$20.00B-$10.00B$0.00$10.00B$20.00B$30.00B$40.00BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Chart Insights

Since a 2023 reporting shift Humana’s revenue mix has concentrated in Insurance and a fast‑scaling CenterWell: Insurance is now the principal growth engine and CenterWell’s patient adds and acquisitions are accelerating top‑line contribution. The sharp Insurance bump in early 2026 likely reflects membership/Medicaid growth and integration timing rather than pure margin improvement. Management’s guidance confirms scale but warns elevated IBNR, higher medical cost trends and a ~91% MLR mean revenue growth won’t automatically convert to sustainable MA margins without pricing, benefit or operational levers.

Data provided by:The Fly

Humana (HUM) vs. SPDR S&P 500 ETF (SPY)

-50%-25%0%25%50%75%100%125%HUM+101.14%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$55.38B
Dividend Yield
0.77%
Average Volume (3M)
1.36M
Price to Earnings (P/E)
44.4
Beta (1Y)
0.93
Revenue Growth
22.02%
EPS Growth
-3.07%
Country
US
Employees
67,060
Sector
Healthcare
Sector Strength
51
Industry
Medical - Healthcare Plans

Humana Business Overview & Revenue Model

Company Description

Humana Inc., a prominent health and well-being enterprise, operates across the United States through its various subsidiary companies. Its operational structure is divided into three main segments: Retail, Group and Specialty, and Healthcare Services...

How the Company Makes Money

Humana primarily makes money by collecting premiums and other payments tied to health plan membership, then managing the cost of members’ medical and pharmacy claims relative to those revenues. 1) Insurance premiums and membership-based payments - Me...

Humana Earnings Call Summary

Earnings Call Date:Nov 06, 2026(Q3-2026)|% Change Since:7.66%|Next Earnings Date:Feb 10, 2027
Earnings Call SentimentPositive

The call was strongly positive. Humana raised its 2026 EPS outlook, reported better-than-expected cost performance, delivered exceptional Stars results, expanded Medicaid and CenterWell membership, improved balance sheet efficiency, and expressed confidence in 2027 margin progress and its 2028 commitments. The main challenges were the continuing Stars headwind, higher expected 2027 cost trends, localized Primary Care Organization pressure, and uncertainty around AEP retention and the eventual size of the 2028 tailwind.

Positive Updates

Raised 2026 Earnings Outlook
Humana raised its full-year 2026 adjusted EPS outlook from at least $9 to at least $9.50. Cost trends for new and existing members are in line to better than expectations, and the company remains on track to double its individual Medicare Advantage pretax margin this year, excluding the Stars headwind.

Negative Updates

Stars Headwind Carries Into 2027
Management said the only known 2027 headwind is the carryover of the Stars headwind from this year. The company also noted that value-based care providers have a 30% cap offset, including on the incremental Stars benefit above the company's target.

Company Guidance

Humana raised its full year 2026 adjusted EPS outlook from at least $9 to at least $9.50 and expects to double its individual MA pretax margin this year, excluding the Stars headwind; for 2027, it anticipates membership will be up, expects fewer new members, and expects to make a material improvement on both a Stars adjusted and Stars unadjusted basis, reaching well into the profitability range, while 2027 trend is expected to be 8% to 9% versus 7% to 8% for 2026, with Part D expected to increase 14% to 15%. The company expects margin progression in '27 to put it on track for a 3% plus margin in 2028, expects a onetime tailwind in 2028, and said 95% of members in 4+ Star plans this year would be upside to its target; it expects to maintain top quartile results for BY '29, with key HEDIS metrics running roughly 5% ahead of last year's quality improvement rate on a per member basis, and said group MA improved 500 basis points excluding the Stars headwind. It also expects approximately 130 basis points of fourth-quarter GAAP debt-to-cap reduction and no substantial change in reinsurance use into 2027.

Humana Financial Statement Overview

Summary

Revenue growth remains strong, but profitability has compressed materially versus 2021–2022 (TTM net margin ~0.9% and lower EBIT/EBITDA margins). Leverage appears manageable with moderate debt-to-equity and rising equity, yet ROE has fallen sharply (~6.7–7.4% in 2024–TTM). Cash flow improved in TTM (OCF $3.7B; FCF $3.1B) but has been volatile over multiple years, lowering confidence in consistency.

Income Statement

72Positive

Balance Sheet

64Positive

Cash Flow

55Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue154.19B129.66B117.81B106.44B92.92B83.65B
Gross Profit20.06B18.85B17.15B18.05B17.23B14.45B
EBITDA3.24B2.91B3.25B4.73B4.81B4.46B
Net Income1.25B1.19B1.21B2.49B2.81B2.93B
Balance Sheet
Total Assets57.28B48.75B46.31B46.89B43.73B44.75B
Cash, Cash Equivalents and Short-Term Investments25.11B4.20B2.22B4.69B5.06B3.39B
Total Debt12.50B12.94B12.26B12.27B11.75B13.22B
Total Liabilities38.40B31.01B29.87B30.57B28.36B28.64B
Stockholders Equity18.82B17.66B16.38B16.26B15.31B16.08B
Cash Flow
Free Cash Flow747.00M375.00M2.39B2.98B3.45B920.00M
Operating Cash Flow1.34B921.00M2.97B3.98B4.59B2.26B
Investing Cash Flow-4.26B2.27B-2.95B-3.49B-1.01B-6.56B
Financing Cash Flow2.08B-1.22B-2.49B-856.00M-1.91B3.02B

Humana Technical Analysis

Technical Analysis SentimentPositive
Last Price443.34

Price Trends

50DMA409.22Positive
100DMA398.37Positive
200DMA317.60Positive

Market Momentum

MACD11.23Negative
RSI68.45Neutral
STOCH93.62Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HUM, the sentiment is Positive. The current price of 443.34 is above the 20-day moving average (MA) of 425.92, above the 50-day MA of 409.22, and above the 200-day MA of 317.60, indicating a bullish trend. The MACD of 11.23 indicates Negative momentum. The RSI at 68.45 is Neutral, neither overbought nor oversold. The STOCH value of 93.62 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HUM.

Humana Risk Analysis

Humana disclosed 16 risk factors in its most recent earnings report. Humana reported the most risks in the "Production" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Production - Risks related to the company’s ability to manufacture goods and services

Latest Risks Added

2 New Risks
1.The number of our Medicare Advantage plans rated 4-star or higher will significantly decline in 2025. We have filed a lawsuit seeking to set aside and vacate the 2025 Star Ratings of our Medicare Advantage plans, but there is no assurance that we will prevail in this lawsuit. If we are not successful, the decline in our Star Ratings will negatively impact our 2026 quality bonus payments from CMS and may also significantly adversely affect our revenues, operating results, and cash flows. In addition, there can be no assurances that we will be successful in maintaining or improving our Star Ratings in future years.Q4, 2024
2.The number of our Medicare Advantage plans rated 4-star or higher are expected to significantly decline in 2025. We have filed a lawsuit seeking to set aside and vacate the 2025 Star Ratings of our Medicare Advantage plans, but there is no assurance that we will prevail in this lawsuit. If we are not successful the decline in our Star Ratings may negatively impact our 2026 quality bonus payments from CMS and may also significantly adversely affect our revenues, operating results, and cash flows.Q3, 2024

Humana Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HUM against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ELVELV76Outperform$96.42B18.9711.59%1.54%3.60%-4.06%
CICI75Outperform$79.09B13.1814.10%2.06%6.79%-0.38%
CVSCVS71Outperform$113.35B10.2114.13%3.00%6.77%2114.64%
CNCCNC66Neutral$37.02B25.266.78%―9.71%―
HUMHUM64Neutral$55.40B44.416.70%0.77%22.02%-3.07%
UNHUNH62Neutral$369.18B23.3916.35%2.20%3.33%-8.75%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%50%100%HUMCNCCICVSUNHELVDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HUM and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HUMHumana443.34217.3996.21%
CNCCentene72.5536.60101.81%
CICigna294.0628.1010.56%
CVSCVS Health Corp85.8111.5415.54%
UNHUnitedhealth Group Inc.389.6888.6129.43%
ELVElevance Health, Inc.433.93123.7339.89%

Humana Corporate Events

Business Operations and StrategyFinancial Disclosures

Humana Reports Third-Quarter Earnings and Business Growth

Positive
Nov 6, 2026

Humana is a health insurer operating an Insurance segment and providing CenterWell Senior Primary Care and Medicaid services, serving insurance members, senior primary-care patients and Medicaid enrollees.On November 6, 2026, Humana reported third-qu...

Business Operations and StrategyFinancial DisclosuresM&A TransactionsPrivate Placements and Financing

Humana Forms New CenterWell Clinics Venture With BlackRock

Positive
Oct 13, 2026

On October 13, 2026, Humana announced a new joint venture with funds and accounts managed by HPS Investment Partners, part of BlackRock, to manage nearly 150 CenterWell Senior Primary Care clinics previously held in ventures with Welsh, Carson, Ander...

Business Operations and StrategyFinancial Disclosures

Humana boosts 2028 Stars revenue outlook, affirms guidance

Positive
Oct 9, 2026

Humana reported that, based on final 2027 Medicare Advantage Star Ratings data for the 2028 bonus year released by CMS on October 8, 2026, it exceeded its goal of achieving top-quartile performance in Stars-related revenue per member. The company pla...

Business Operations and StrategyFinancial Disclosures

Humana Reaffirms 2026 Earnings Guidance to Investors

Positive
Sep 1, 2026

Humana said members of its senior management team planned to meet investors and analysts between September 1 and September 30, 2026, where they intended to reaffirm full-year 2026 guidance of at least $6.52 in GAAP diluted EPS and at least $9.00 in a...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026